Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER+, HER2- Advanced Breast Cancer”

234 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 234 results

Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Early research (Phase 1)Looking for participantsNCT06784193
What this trial is testing

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Olema Pharmaceuticals, Inc. 180
Not applicableStudy completedNCT06607601
What this trial is testing

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

Who this might be right for
Metastatic Breast Cancer
Aetion, Inc. 724
Testing effectiveness (Phase 2)Looking for participantsNCT05933395
What this trial is testing

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Who this might be right for
Advanced Breast Cancer
Dartmouth-Hitchcock Medical Center 135
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Large-scale testing (Phase 3)UnknownNCT04753177
What this trial is testing

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Who this might be right for
The Neoadjuvant Therapy
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary 120
Testing effectiveness (Phase 2)UnknownNCT00687648
What this trial is testing

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Centre, Singapore 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759248
What this trial is testing

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 55
Early research (Phase 1)Study completedNCT01971515
What this trial is testing

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumor
EMD Serono 101
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Early research (Phase 1)Study completedNCT01238952
What this trial is testing

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 4
Testing effectiveness (Phase 2)Study completedNCT03250676
What this trial is testing

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more
Eisai Inc. 151
Testing effectiveness (Phase 2)Ended earlyNCT00206492
What this trial is testing

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Who this might be right for
Breast Cancer
Baylor Breast Care Center 3
Early research (Phase 1)WithdrawnNCT02627430
What this trial is testing

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeFallopian Tube Serous Neoplasm+10 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Early research (Phase 1)Study completedNCT02499146
What this trial is testing

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 26
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Load More Results